For InsRmod/high in all patients, the results became significant HRadj 0.60 (95%CI 0.37-0.97), while for IGF1Rstrong the subgroup of AI-treated patients >50 years old with ER+ tumors, the results became non-significant when using the IGF1R status for the contralateral tumor. The gene discussed is IGF1R; the disease is neoplasm.